GT101
Phase 1Biologic
GT101 is one of 34 biologic programs targeting Advanced Solid Tumors. It is currently in Phase 1.
2
Indications
3
Total Trials
3
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
286 competitors in Advanced Solid Tumors
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePhase 2
Alimta
SShawn Eagle
Phase 2
Trifluridine/tipiracil
AbbViePhase 2
BNT327
BioNTechPhase 2
Standard Chemotherapy
RochePhase 2
IL-2
FFate Therapeutics
Phase 2
Anti-PD-1 Monoclonal Antibody
IiTeos Therapeutics
Phase 2
YL201
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
GT201
GGrit Biotechnology
Phase 2
CEA-Targeted CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cervical Cancer1 trial
Advanced Solid Tumors1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GT101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- GGrit Biotechnology